Aclacinomycin A stabilizes topoisomerase I covalent complexes

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4564-4569

  Nitiss, John L ^a   Pourquier, Philippe ^b   Pommier, Yves ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLACINOMYCIN; ACLARUBICIN; AMSACRINE; DNA TOPOISOMERASE; DOXORUBICIN; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; COMPETITIVE INHIBITION; COMPLEX FORMATION; COVALENT BOND; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STABILITY; INTERCALATION COMPLEX; NONHUMAN; PRIORITY JOURNAL; TARGET CELL;

ACLARUBICIN; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; GENOTYPE; HUMANS; KINETICS; OLIGODEOXYRIBONUCLEOTIDES; SACCHAROMYCES CEREVISIAE; SUBSTRATE SPECIFICITY;

EID: 0030827993     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
2. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin. Oncol., 23: 3-10, 1996.
3. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta., 1262: 1-14, 1995.
4. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Intercalate antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259 9182-9187, 1984.
5. Chen, G. L., Yang, L., Rowe, T. C., Halligan, B. D., Tewey, K. M., and Liu, L. F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259: 13560-13566, 1984.
6. Pommier, Y., Schwartz, R. E., Zwelling, L. A., and Kohn, K. W. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry, 24: 6406-6410, 1985.
7. Froelich-Ammon, S. J., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.
8. Poddevin, B., Riou, J. F., Lavelle, F., and Pommier, Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol. Pharmacol., 44: 767-774, 1993.
9. Riou, J. F., Fosse, P., Nguyen, C. H., Larsen, A. K., Bissery, M. C., Grondard, L., Saucier, J. M., Bisagni, E., and Lavelle, F. Intoplicine (RP 60475), and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res., 53: 5987-5993, 1993.
10. Leteurtre, F., Fujimori, A., Tanizawa, A., Chhabra, A., Mazumder, A., Kohlhagen, G., Nakano, H., and Pommier, Y. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J. Biol. Chem., 269: 28702-28707, 1994.
11. Yamashita, Y., Saitoh, Y., Ando, K., Takahashi, K., Ohno, H., and Nakano, H. Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces (Letter). J. Antibiot. (Tokyo), 43: 1344-1346, 1990.
12. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
13. Lynch, T. J., Jr., Kalish, L., Strauss, G., Elias, A., Skarin, A., Shulman, L. N., and Posner, M. Phase II study of topotecan in metastatic non-small-cell lung cancer. J. Clin. Oncol., 12: 347-352, 1994.
14. Slichenmyer, W. J., Rowinsky, E. K., Grochow, L. B., Kaufmann, S. H., and Donehower, R. C. Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother. Pharmacol., 34 (Suppl.): S53-S57, 1994.
15. Rothenberg, M. L. CPT-11: an original spectrum of clinical activity. Semin. Oncol., 23: 21-26, 1996.
16. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
17. Wassermann, K., Markovits, J., Jaxel, C., Capranico, G., Kohn, K. W., and Pommier, Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol., 38: 38-45, 1990.
18. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. Effects of quinolone derivatives on eukaryotic topoisomerase II: a novel mechanism for enhancement of enzyme-mediated DNA cleavage. J. Biol. Chem., 266: 14585-14592, 1991.
19. Sinha, B. K., Politi, P. M., Eliot, H. M., Kerrigan, D., and Pommier, Y. Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide. Eur. J. Cancer. 26: 590-593, 1990.
20. Nitiss, J. L., Liu, Y. X., Harbury, P., Jannatipour, M., Wasserman, R., and Wang, J. C. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res., 52: 4467-4472, 1992.
21. Nitiss, J. L., Liu, Y. X., and Hsiung, Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res., 53: 89-93, 1993.
22. Liu, L. F. Topoisomerase poisons in cell killing and drug resistance. Pezcoller Found. Symp., 1: 251-269, 1990.
23. Nitiss, J. L. Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother. Pharmacol., 34 (Suppl.): S6-S13, 1994.
24. Wang, J. C. DNA topoisomerases. Ann. Rev. Biochem., 65: 635-692, 1996.
25. Corbett, A. H., Hong, D., and Osheroff, N. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J. Biol. Chem., 268: 14394-14398, 1993.
26. Sugino, A., Higgins, N. P., Brown, P. O., Peebles, C. L., and Cozzarelli, N. R. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc. Natl. Acad. Sci. USA, 75: 4838-4842, 1978.
27. Sehested, M., and Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 51: 879-886, 1996.
28. Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K. R., Tanabe, K., and Andoh, T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res., 51: 4909-4916, 1991.
29. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA, 91: 1781-1785, 1994.
30. Beck, W. T., Kim, R., and Chen, M. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Cancer Chemother. Pharmacol., 34 (Suppl.): S14-S18, 1994.
31. Drake, F. H., Hofmann, G. A., Mong, S. M., Bartus, J. O., Hertzberg, R. P., Johnson, R. K., Mattern, M. R., and Mirabelli, C. K. In vitro and intracellular inhibition of topoisomerase D by the antitumor agent merbarone. Cancer Res., 49: 2578-2583, 1989.
32. Jensen, P. B., Sørensen, B. S., Demant, E. J., Sehested, M., Jensen, P. S., Vindeløv, L., and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res., 50: 3311-3316, 1990.
33. Jensen, P. B., Jensen, P. S., Demant, E. J., Friche, E., Sørensen, B. S., Sehested, M., Wassermann, K., Vindeløv, L., Westergaard, O., and Hansen, H. H. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res., 51: 5093-5099, 1991.
34. Nitiss, J. L. Roles of DNA topoisomerases in chromosomal replication and segregation. Adv. Pharmacol., 29: 103-134, 1994.
35. Petersen, L. N., Jensen, P. B., Sørensen, B. S., Engelholm, S. A., and Spang-Thomsen, M. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16. Invest. New Drugs, 12: 289-297, 1994.
36. Nitiss, J. L., and Wang, J. C. Yeast as a genetic system in the dissection of the mechanism of cell killing by topoisomerase-targeting anti-cancer drugs. In: M. Potmesil and K. Kohn (eds.), DNA Topoisomerases and Cancer, pp. 77-91. London: Oxford University Press, 1991.
37. Jannatipour, M., Liu, Y. X., and Nitiss, J. L. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J. Biol. Chem., 268: 18586-18592, 1993.
38. Rossi, F., Labourier, E., Forne, T., Divita, G., Derancourt, J., Riou, J. F., Antoine, E., Cathaia, G., Brunel, C., and Tazi, J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature (Lond.), 381: 80-82, 1996.
39. Pommier, Y., Jenkins, J., Kohlhagen, G., and Leteurtre, F. DNA recombinase activity of eukaryotic DNA topoisomerase I: effects of camptothecin and other inhibitors. Mutat. Res., 337: 135-145 1995.
40. Zhelkovsky, A. M., and Moore, C. L. Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector. Protein Expr. Purif., 5: 364-370, 1994.
41. Ishida, R., Hamatake, M., Wasserman, R. A., Nitiss, J. L., Wang, J. C., and Andoh, T. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res., 55: 2299-2303, 1995.
42. Nitiss, J. L. Yeast as a genetic model system for studying topoisomerase inhibitors. Adv. Pharmacol., 29B: 201-226, 1994.
43. Gietz, R. D., and Sugino, A. New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene, 74: 527-534, 1988.
44. Bonven, B. J., Gocke, E., and Westergaard, O. A high affinity topoisomerase I binding sequence is clustered at DNase I hypersensitive sites in Tetrahymena R-chromatin. Cell, 41: 541-551, 1985.
45. Thomsen, B., Mollerup, S., Bonven, B. J., Frank, R., Blocker, H., Nielsen, O. F., and Westergaard, O. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin. EMBO J., 6: 1817-1823, 1987.
46. Pommier, Y., Kohlhagen, G., Kohn, K. W., Leteurtre, F., Wani, M. C., and Wall, M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. USA, 92: 8861-5, 1995.
47. Nitiss, J., and Wang, J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501-7505, 1988.
48. Eng, W. K., Faucette, L., Johnson, R. K., and Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 34: 755-760, 1988.
49. Trask, D. K., and Muller, M. T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA, 85; 1417-1421, 1988.
50. Sorensen, B. S., Jensen, P. B., Sehested, M., Jensen, P. S., Kjeldsen, E., Nielsen, O. F., and Alsner, J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. Biochem. Pharmacol., 47: 2105-2110, 1994.
51. Shelton, C. J., Harding, M. M., and Prakash, A. S. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains. Biochemistry, 35: 7974-7982, 1996.
52. Yang, D., and Wang, A. H. Structure by NMR of antitumor drugs aclacinomycin A and B complexed to d(CGTACG). Biochemistry, 33: 6595-6604, 1994.
53. Gao, Y. G., and Wang, A. H. Crystal structures of four morpholino-doxorubicin anticancer drugs complexed with d(CGTACG) and d(CGATCG): implications in drug-DNA crosslink. J. Biomol. Struct. Dyn., 13: 103-117, 1995.
54. Chen, A. Y., Yu, C., Gatto, B., and Liu, L. F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA, 90: 8131-8135, 1993.
55. Cheng, M. F., Chatterjee, S., and Berger, N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res., 6: 269-279, 1994.
56. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., Houghton, J. A., and Hallman, J. D. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
57. Nitiss, J. L., and Wang, J. C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol., 50; 1095-1102, 1996.
58. Hsiang, Y. H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
59. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.